Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations

Tirkkonen, M ; Johannsson, O LU ; Agnarsson, B A ; Olsson, Håkan LU orcid ; Ingvarsson, S LU ; Karhu, R ; Tanner, M ; Isola, J LU ; Barkardottir, R B and Borg, Åke LU , et al. (1997) In Cancer Research 57(7). p.7-1222
Abstract

BRCA1 and BRCA2 mutations confer increased risk for development of breast cancer, but a number of additional, currently largely unknown, somatic genetic defects must also accumulate in the breast epithelial cells before malignancy develops. To evaluate the nature of these additional somatic genetic defects, we performed a genome-wide survey by comparative genomic hybridization on breast cancers from 21 BRCA1 mutation carriers, 15 BRCA2 mutation carriers, and 55 unselected controls. The total number of genetic changes was almost two times higher in tumors from both BRCA1 and BRCA2 mutation carriers than in the control group. In BRCA1 tumors, losses of 5q (86%), 4q (81%), 4p (64%), 2q (40%), and 12q (40%) were significantly more common... (More)

BRCA1 and BRCA2 mutations confer increased risk for development of breast cancer, but a number of additional, currently largely unknown, somatic genetic defects must also accumulate in the breast epithelial cells before malignancy develops. To evaluate the nature of these additional somatic genetic defects, we performed a genome-wide survey by comparative genomic hybridization on breast cancers from 21 BRCA1 mutation carriers, 15 BRCA2 mutation carriers, and 55 unselected controls. The total number of genetic changes was almost two times higher in tumors from both BRCA1 and BRCA2 mutation carriers than in the control group. In BRCA1 tumors, losses of 5q (86%), 4q (81%), 4p (64%), 2q (40%), and 12q (40%) were significantly more common than in the control group (7-13%). BRCA2 tumors were characterized by a higher frequency of 13q (73%) and 6q (60%) losses and gains of 17q22-q24 (87%) and 20q13 (60%) as compared to the prevalence of these changes in the control group (12-18%). In conclusion, accumulation of somatic genetic changes during tumor progression may follow a unique pathway in individuals genetically predisposed to cancer, especially by the BRCA1 gene. Activation or loss of genes in the affected chromosomal regions may be selected for during tumor progression in cells lacking functional BRCA1 or BRCA2. Identification of such genes could provide targets for therapeutic intervention and early diagnosis.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Adult, Aged, Aged, 80 and over, BRCA2 Protein, Breast Neoplasms, Carcinoma, Ductal, Breast, Chromosome Deletion, Chromosomes, Human, Pair 4, Chromosomes, Human, Pair 5, Disease Progression, Female, Genes, BRCA1, Germ-Line Mutation, Heterozygote, Humans, Middle Aged, Neoplasm Proteins, Nucleic Acid Hybridization, Polymorphism, Single-Stranded Conformational, Transcription Factors
in
Cancer Research
volume
57
issue
7
pages
6 pages
publisher
American Association for Cancer Research Inc.
external identifiers
  • scopus:0030894785
  • pmid:9102202
ISSN
0008-5472
language
English
LU publication?
yes
id
dfd9e5d1-0f4e-45ae-acfb-1aec307ed336
date added to LUP
2016-09-18 12:47:40
date last changed
2024-04-05 04:51:15
@article{dfd9e5d1-0f4e-45ae-acfb-1aec307ed336,
  abstract     = {{<p>BRCA1 and BRCA2 mutations confer increased risk for development of breast cancer, but a number of additional, currently largely unknown, somatic genetic defects must also accumulate in the breast epithelial cells before malignancy develops. To evaluate the nature of these additional somatic genetic defects, we performed a genome-wide survey by comparative genomic hybridization on breast cancers from 21 BRCA1 mutation carriers, 15 BRCA2 mutation carriers, and 55 unselected controls. The total number of genetic changes was almost two times higher in tumors from both BRCA1 and BRCA2 mutation carriers than in the control group. In BRCA1 tumors, losses of 5q (86%), 4q (81%), 4p (64%), 2q (40%), and 12q (40%) were significantly more common than in the control group (7-13%). BRCA2 tumors were characterized by a higher frequency of 13q (73%) and 6q (60%) losses and gains of 17q22-q24 (87%) and 20q13 (60%) as compared to the prevalence of these changes in the control group (12-18%). In conclusion, accumulation of somatic genetic changes during tumor progression may follow a unique pathway in individuals genetically predisposed to cancer, especially by the BRCA1 gene. Activation or loss of genes in the affected chromosomal regions may be selected for during tumor progression in cells lacking functional BRCA1 or BRCA2. Identification of such genes could provide targets for therapeutic intervention and early diagnosis.</p>}},
  author       = {{Tirkkonen, M and Johannsson, O and Agnarsson, B A and Olsson, Håkan and Ingvarsson, S and Karhu, R and Tanner, M and Isola, J and Barkardottir, R B and Borg, Åke and Kallioniemi, O P}},
  issn         = {{0008-5472}},
  keywords     = {{Adult; Aged; Aged, 80 and over; BRCA2 Protein; Breast Neoplasms; Carcinoma, Ductal, Breast; Chromosome Deletion; Chromosomes, Human, Pair 4; Chromosomes, Human, Pair 5; Disease Progression; Female; Genes, BRCA1; Germ-Line Mutation; Heterozygote; Humans; Middle Aged; Neoplasm Proteins; Nucleic Acid Hybridization; Polymorphism, Single-Stranded Conformational; Transcription Factors}},
  language     = {{eng}},
  month        = {{04}},
  number       = {{7}},
  pages        = {{7--1222}},
  publisher    = {{American Association for Cancer Research Inc.}},
  series       = {{Cancer Research}},
  title        = {{Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations}},
  volume       = {{57}},
  year         = {{1997}},
}